Among these therapies, neratinib, a pan-HER tyrosine kinase inhibitor (TKI), has demonstrated promising clinical efficacy in both monotherapy- and combination regimens in patients with various solid tumors harboring ERBB2 oncogenic variants, including breast, biliary tract, cervical, and non-small cell lung cancer [8–11]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.